US · Healthcare · Biotechnology
EPS came in at 12.53 against a street estimate of 8.00 — a beat of 56.6%.
Analysts rate Regeneron Pharmaceuticals Inc a buy (19 buy, 8 hold, 1 sell out of 28) with an average price target of $863.93.
CONFIDENT REGN posted 17% revenue growth and 11% non-GAAP EPS growth, driven by Dupixen (+38%), EYLEA HD (+52%), and Libtayo (+29%). Pipeline advancing with FDA decisions expected on cemdisiran (GMG) in November and garituzimab (FOP) in August. Sanofi development balance fully repaid, boosting future collaboration margins. Q2 2026 EYLEA HD and EYLEA delivered $1B+ combined U.S. Q2 sales. Dupixen U.S. $4.6B. International growth ongoing through Sanofi (Dupixen, EYLEA) and Bayer (EYLEA outside U.S.). Full Sanofi development balance repayment beginning Q3 2026 to unlock higher collaboration margins. Analysts pressed M&A readiness given $15B cash and Sanofi repayment, Sanofi partnership expansion, EYLEA HD prefilled syringe timeline and manufacturing scale, cemdisiran GMG competitive positioning vs. FCRN leaders, obesity combo differentiation vs. mature GLP-1 market, and solid tumor strategy…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.85% |
| Vanguard Capital Management, LLC | 6.44% |
| Dodge & Cox | 4.73% |
| State Street Corp | 4.70% |
| Amvescap Plc. | 3.83% |
| JPMorgan Chase & Co | 3.67% |
| Vanguard Portfolio Management, LLC | 3.08% |
| Franklin Templeton Inc | 2.69% |
| Document | Date |
|---|---|
| Results announced · Q4 2026 HEADLINE NUMBERS • Regeneron and Sanofi signed the Sixth Amendment to their collaboration agreement on October 1, 2026. • Sanofi will pay Regeneron | 2026-10-06 |
| Board / officer change · Q3 2026 HEADLINE NUMBERS • Regeneron granted one-time, performance-based awards to CEO Leonard S. Schleifer and CSO George D. Yancopoulos on September 24, 20 | 2026-09-30 |
| Quarterly report · Q2 2026 REGENERON PHARMACEUTICALS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net income Q2 2026: $1,296.9 million | Q2 2025: $1,391.6 million (down 6.8 | 2026-07-30 |
| Results announced · Q3 2026 REGENERON PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 total revenues: $4.3 billion, up 17% versus Q2 2025 ($3.7 billion) • | 2026-07-30 |
| Results announced · Q3 2026 REGENERON PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Acquired in-process research and development (IPR&D) charge of approximately $ | 2026-07-06 |
| Shareholder vote results · Q2 2026 REGENERON PHARMACEUTICALS, INC. — 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 12, 2026 • Company trades on NASDAQ under tick | 2026-06-17 |
| Quarterly report · Q1 2026 REGENERON PHARMACEUTICALS, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenues Q1 2026: $3,605.4 million, up 19% from $3,028.7 million in | 2026-04-29 |
| Results announced · Q2 2026 REGENERON Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenues: $3.6 billion (up 19% vs Q1 2025: $3.0 billion) • GAAP net income: $727 millio | 2026-04-29 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.94 / share ex-date Aug 18, 2026 · pay Aug 31, 2026 | 2026-08-18 |
| Dividend | $0.94 / share ex-date May 20, 2026 · pay Jun 4, 2026 | 2026-05-20 |
| Dividend | $0.94 / share ex-date Feb 20, 2026 · pay Mar 5, 2026 | 2026-02-20 |
| Dividend | $0.88 / share ex-date Nov 20, 2025 · pay Dec 5, 2025 | 2025-11-20 |
| Announcement | Date |
|---|---|
| Sanofi partnership adds four antibodies with $1 billion upfront and up to $7 billion milestones Regeneron and Sanofi expanded their long-running partnership to jointly develop and commercialize four new long-acting antibodies invented by Regeneron, targeting IL-13, IL-4, IL-4Rα, and IL | 2026-10-06 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Regeneron Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.